维多利祖马布与乌帕达西提尼布在克罗恩氏病的现实世界比较有效性通过52周
Rahul S Dalal1, Alex Carlin, Heidy Cabral
1Department of Medicine, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Journal of clinical gastroenterology
|December 18, 2025
概括
在克罗恩氏病 (CD) 患者中,相比于 vedolizumab,upadacitinib 在12周内显示出更快的临床反应. 然而,这两种治疗方法在52周内表现出类似的长期有效性,耐用性和安全性.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对于克罗恩病 (CD) 中的vedolizumab和upadacitinib,现实世界的比较数据很少.
- 了解治疗差异对于优化CD管理至关重要.
研究的目的:
- 为了比较52周的疗效,耐久性和安全性,在成年患者中,韦多利祖马布和乌帕达西提尼布的有效性,耐久性和安全性.
- 评估临床反应,无类固醇临床缓解和治疗中止率.
主要方法:
- 一项对139名成人CD患者进行的回顾性队列研究,这些患者开始服用vedolizumab或upadacitinib.
- 利用治疗权重的逆概率来平衡混因素.
- 评估了无类固醇临床缓解和在12周和52周停止治疗的共同主要结果.
主要成果:
- 与vedolizumab相比,upadacitinib在12周内显示出显著更高的临床反应可能性.
- 在这两种治疗方法之间没有观察到任何显著的差异,即在52周内无固醇临床缓解或停止治疗.
- 由于不良事件而导致的不良事件和中止率在vedolizumab和upadacitinib之间是可比的.
结论:
- 在CD患者中,upadacitinib提供了更快的初始临床反应.
- 维多利祖马布和乌帕达西提尼布在52周的时间内表现出类似的长期疗效,耐用性和安全性.
- 治疗选择可能取决于在积极的CD管理中所需的反应速度.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
445
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
445
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
459
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
459
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
408
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
408
Drugs for Treatment of Ulcerative Colitis in IBD
424
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
424
Inflammatory Bowel Disease IV: Pharmacological Management
445
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
445
Inflammatory Bowel Disease II: Crohn's Disease
915
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
915


